DDInter351 DDInter1435
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Chloramphenicol {u} (Compound) binds {v} (Gene) CYP3A5
Chloramphenicol {u} (Compound) upregulates {v} (Gene) CCNH
Chloramphenicol {u} (Compound) is included by {v} (Pharmacologic Class) Amphenicols
Chloramphenicol {u} (Compound) downregulates {v} (Gene) USP22
Chloramphenicol {u} (Compound) causes {v} (Side Effect) Angioedema
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elotuzumab
Chloramphenicol {u} may lead to a major life threatening interaction when taken with {v} Flibanserin
Chloramphenicol (Compound) binds CYP3A5 (Gene)
Chloramphenicol (Compound) upregulates CCNH (Gene)
Chloramphenicol (Compound) is included by Amphenicols (Pharmacologic Class)
Chloramphenicol (Compound) downregulates USP22 (Gene)
Chloramphenicol (Compound) causes Angioedema (Side Effect)
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Donepezil
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Chloramphenicol may lead to a major life threatening interaction when taken with Flibanserin